Sansana Sawasdikosol

Summary

Affiliation: Mount Sinai School of Medicine
Country: USA

Publications

  1. ncbi HPK1 as a novel target for cancer immunotherapy
    Sansana Sawasdikosol
    Department of Oncological Sciences, Tisch Cancer Institute, Mount Sinai School of Medicine, 1425 Madison Avenue, Icahn 15 75B, New York, NY 10029, USA
    Immunol Res 54:262-5. 2012
  2. ncbi Hematopoietic progenitor kinase 1 is a critical component of prostaglandin E2-mediated suppression of the anti-tumor immune response
    Saba Alzabin
    NYU Cancer Institute, Department of Medicine, New York University School of Medicine, New York, 10016, USA
    Cancer Immunol Immunother 59:419-29. 2010
  3. ncbi Prostaglandin E2 activates HPK1 kinase activity via a PKA-dependent pathway
    Sansana Sawasdikosol
    New York University School of Medicine, New York University Cancer Institute, New York, New York 10016 6402, USA
    J Biol Chem 282:34693-9. 2007
  4. ncbi Detecting tyrosine-phosphorylated proteins by Western blot analysis
    Sansana Sawasdikosol
    Mount Sinai School of Medicine, New York, New York, USA
    Curr Protoc Immunol . 2010
  5. ncbi Hematopoietic progenitor kinase 1 is a negative regulator of dendritic cell activation
    Saba Alzabin
    Department of Pathology, New York University Cancer Institute, New York University School of Medicine, New York, NY 10016, USA
    J Immunol 182:6187-94. 2009

Collaborators

Detail Information

Publications5

  1. ncbi HPK1 as a novel target for cancer immunotherapy
    Sansana Sawasdikosol
    Department of Oncological Sciences, Tisch Cancer Institute, Mount Sinai School of Medicine, 1425 Madison Avenue, Icahn 15 75B, New York, NY 10029, USA
    Immunol Res 54:262-5. 2012
    ..Given that HPK1 is not expressed in any major organs, it is less likely that an inhibitor of HPK1 kinase activity would cause any serious side effects...
  2. ncbi Hematopoietic progenitor kinase 1 is a critical component of prostaglandin E2-mediated suppression of the anti-tumor immune response
    Saba Alzabin
    NYU Cancer Institute, Department of Medicine, New York University School of Medicine, New York, 10016, USA
    Cancer Immunol Immunother 59:419-29. 2010
    ..We conclude that PGE(2) utilizes HPK1 to suppress T cell-mediated anti-tumor responses...
  3. ncbi Prostaglandin E2 activates HPK1 kinase activity via a PKA-dependent pathway
    Sansana Sawasdikosol
    New York University School of Medicine, New York University Cancer Institute, New York, New York 10016 6402, USA
    J Biol Chem 282:34693-9. 2007
    ..We speculate that this unique signaling pathway enables PGE(2) signals to engage a proven negative regulator of TCR signal transduction pathway and uses it to inhibit T cell activation...
  4. ncbi Detecting tyrosine-phosphorylated proteins by Western blot analysis
    Sansana Sawasdikosol
    Mount Sinai School of Medicine, New York, New York, USA
    Curr Protoc Immunol . 2010
    ..This unit will describe in detail the steps needed to perform the standard anti-phosphotyrosine western blot analysis...
  5. ncbi Hematopoietic progenitor kinase 1 is a negative regulator of dendritic cell activation
    Saba Alzabin
    Department of Pathology, New York University Cancer Institute, New York University School of Medicine, New York, NY 10016, USA
    J Immunol 182:6187-94. 2009
    ..c. Lewis Lung Carcinoma more efficiently than their WT counterpart. Our data reveal a novel role for HPK1 as a negative regulator of DC functions, identifying its potential as a molecular target for DC-based immunotherapy against cancers...